Imaging biomarkers of inflammation in situ with functionalized quantum dots in the dextran sodium sulfate (DSS) model of mouse colitis by Karwa, Amol et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
College of Arts and Sciences 
    
      
 
Drexel E-Repository and Archive (iDEA) 
http://idea.library.drexel.edu/   
 
 
Drexel University Libraries 
www.library.drexel.edu
 
 
 
 
 
 
 
 
 
 
 
The following item is made available as a courtesy to scholars by the author(s) and Drexel University Library and may 
contain materials and content, including computer code and tags, artwork, text, graphics, images, and illustrations 
(Material) which may be protected by copyright law. Unless otherwise noted, the Material is made available for non 
profit and educational purposes, such as research, teaching and private study. For these limited purposes, you may 
reproduce (print, download or make copies) the Material without prior permission. All copies must include any 
copyright notice originally included with the Material. You must seek permission from the authors or copyright 
owners for all uses that are not allowed by fair use and other provisions of the U.S. Copyright Law. The 
responsibility for making an independent legal assessment and securing any necessary permission rests with persons 
desiring to reproduce or use the Material. 
 
 
Please direct questions to archives@drexel.edu
 
IMAGING BIOMARKERS OF INFLAMMATION IN SITU WITH 
FUNTIONALIZED QUANTUM DOTS IN THE DEXTRAN SODIUM 
SULFATE (DSS) MODEL OF MOUSE COLITIS 
 
Amol Karwa1, Elisabeth Papazoglou1, Kambiz Pourrezaei1,  
Som Tyagi2 and Sreekant Murthy3* 
 
1. School of Biomedical Engineering, Science and Health     
             Systems, Drexel University 
2. Department of Physics, Drexel University 
3. Division of Gastroenterology and Hepatology,  
                         Drexel  University College of Medicine  
* Author to whom correspondence should be addressed: 
Sreekant Murthy, Ph.D., Professor of Medicine, Mail Stop 444, Drexel University College 
of Medicine, 245 N 15th Street , Philadelphia, Pa 19102, Tel: 215 762 3722, Fax: 215 762 
3722, e-mail: S.Murthy@drexel.edu 
 
 
 
 
 
 
 
 
 
 
 1
Abstract:   
Objective and Design: Myeloperoxidase (MPO) and proinflammatory cytokines play an 
important role in the development of inflammation.  These markers are generally 
measured using tedious ELISA procedures.  In this study, a novel technique utilizing 
antibody conjugated quantum dot nanoparticles was developed to detect 
myeloperoxidase, IL-1 α and TNF-α in vivo in the dextran sodium sulfate (DSS) model 
of experimental colitis. Materials and Methods: Colitis was induced in animals (n=8 
animals/ group) by feeding 4% DSS solution ad libitum for seven to eight days. 
Quantum Dots exhibiting fluorescence at various wavelengths were conjugated to 
MPO, IL-1 α and TNF-α polyclonal antibodies and tested in vivo at various stages of 
colitis. Tissue sections obtained were imaged with confocal microscope. The image 
intensity obtained from the tissue specimen was correlated with clinical activity 
measured as Disease Activity Index (DAI). 
Results: Myeloperoxidase, IL-1α and TNF-α were visualized with quantum dots on 
various days of disease. The intensity of quantum dots increased with increase in 
inflammation. The increase in intensity showed an excellent correlation with the DAI 
based on the clinical parameters.  
 Conclusion: The study demonstrated that multiple biomarkers can be detected 
simultaneously and their quantitative expression correlated well with clinical disease 
severity.  This novel technology should facilitate design of a novel optical platform for 
imaging various biomarkers of inflammation, early detection of acute and chronic 
disease markers and inflammation-mediated cancer markers. This detection may also 
facilitate determination of therapeutic success. 
 2
Key Words : Inflammation, Colitis, Animal Model of Colitis, Quantum 
Dots, Myeloperoxidase, Dextran Sodium Sulfate, TNFα, IL1α, 
nanotechnology. 
 
Introduction 
Inflammation is a complex systemic and local response by the host immune system to 
harmful stimuli such as infection and noxious chemicals interacting with the local 
immune system [1, 2]. The inflammatory response is usually characterized by an acute 
response which may gradually progress into chronic inflammation [2, 3]. The 
inflammation is marked by the accumulation and activation of phagocytic leukocytes at 
the site of the injury. Development of the inflammatory process and recruitment of 
leukocytes is controlled by cytokines, lipid mediators and other chemotactic factors 
produced by the immune response or in consequence to an inflammatory response [3, 
4]. In acute inflammation, polymorphonuclear leukocytes (PMNs) or neutrophils form 
the first line of defense and appear immediately at the site of injury. Once at the site of 
injury, these leukocytes get attached to the endothelial cells and may eliminate the 
inflammatory stimuli by phagocytosis, respiratory burst and release of cytotoxic 
mediators and proteases [5-7]. The cytotoxic mediators are reactive oxygen metabolites 
consisting of highly reactive oxygen species (ROS) such as superoxide anions, hydrogen 
peroxide and HOCl (hypochlorous acid) and the enzyme myeloperoxidase (MPO) 
secreted by neutrophils. These reactive radicals and other oxidants when produced 
uncontrollably may injure cells and tissue directly, via oxidative degradation of essential 
cellular components [6, 8-11].  Given the undisputed role MPO plays in ROS mediated 
tissue injury it has been used as an important relatively stable inflammation and 
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oxidative stress marker to quantify the PMN’s accumulation and infiltration in a variety 
of pathological processes accompanied by inflammation [12-15] Likewise, cytokines 
which have pleiotropic, overlapping and sometimes contradictory functions depending 
on their concentration contribute to the signs, symptoms, and pathology of 
inflammatory, infectious, autoimmune, and malignant diseases. Tumor necrotic factor 
alpha (TNF-α) and IL-1 are an excellent example of such action [16, 17]. Early detection 
of inflammation and immunologic response would provide clues to the underlying 
pathobiology of many inflammatory and autoimmune diseases and would enable more 
effective diagnosis and treatment of those patients.  However, many inflammatory 
markers do not lend themselves well to routine clinical use because they are difficult to 
measure in a standardized manner or because their expression (location and 
concentration) is highly variable. A lack of standardization for the various assays used is 
a major setback especially when there is no consensus regarding a reliable or precise 
assay.  
In order to overcome the limitations of the above mentioned assays and to provide a 
direct measurement of MPO, TNF-α and IL-1, it has become necessary to measure these 
markers directly at the site of inflammation. Here we demonstrate a novel method of 
targeting MPO, TNF-α and IL-1α in situ in the colon, in the dextran sodium sulfate 
(DSS) model of experimental colitis in mice using fluorescent nanoparticles called 
Quantum Dots (QDs). The technique allowed direct visualization of these biomarkers, 
quantification of their expression and correlation with increase in clinical disease activity 
over a period of time. We were able to quantify inflammation in terms of fluorescence 
intensity of MPO expressed and targeted with QDs.  
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Animal models are the most representative model of human diseases and hence serve as 
important agents to understand the molecular mechanisms involved in the pathogenesis 
of diseases and as preclinical tools for the development of novel therapeutics. In this 
regard, the dextran sodium sulfate (DSS) model of experimental colitis has been used 
extensively by us [18-21] and others [22-26]  as a useful model for  the detection of 
various biomarkers as well as in the preclinical evaluation of various existing and 
emerging therapies.   The model shows progressive inflammation and given the 
advantages of QDs, it could be possible to image this progression of disease from its 
inception to the full blown state, by targeting a stable marker of disease progression. 
Since this model shows increased levels of MPO and ROS, TNF-α and IL-1 [21, 27, 28] 
we conjugated MPO, TNF-α and IL-1 antibodies to three different color QDs and tested 
these bioprobes in our model. The intensity of QDs was calculated from confocal images 
of tissue sections and plotted with respect to the disease severity index to demonstrate 
the clinical correlation of these markers with active disease in this mouse model.  
MATERIALS AND METHODS 
 
Quantum dot conjugation with specific antibodies 
Different color QDs with emission maximum at different wavelength were obtained 
from Quantum Dot Corporation (QDC, Hayward, currently Invitrogen). Polyclonal IgG 
MPO antibody (SCBT, Santacruz ), anti-testosterone antibody (Research Diagnostics, 
NJ ), anti-TNF-a and IL-1a antibodies (ebioscience, San Diego CA) were conjugated to 
these QDs.    
Quantum dot nanocrystals are composed of a CdSe core capped with a ZnS shell and 
coated with an amine terminated polymer.  Conjugation of QD’s to each of the 
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antibodies was accomplished by converting the amine groups on the QDs to thiol 
reactive maleimide groups using a hetero-bifunctional crosslinker, 4-
(maleimidomethyl)-1-cyclohexanecarboxylic acid N-hydroxysuccinimide ester (SMCC). 
Antibodies were treated with Dithiothreitol (DTT), thus reducing some of the disulfide 
bonds to produce thiol groups. The final conjugation was carried out by coupling the 
thiol groups with the maleimide functional groups on the QDs. The QD-antibody 
conjugation and purification procedures were conducted following the manufacturer’s 
suggested protocols [29]. 
Animal studies 
All animal studies were approved by the IACUC of Drexel University College of 
Medicine and were performed in accordance with guidelines established by the 
National Institutes of Health on the use of experimental animals. 
 
Female eight-week old, Swiss Webster ice weighing 25 – 30 g were used to produce 
either physical injury or DSS-induced experimental colitis. The animals were housed in 
vivarium conditions at 23 C and 12-h light/dark cycles.  Mice were fed standard mice 
chow pellets and had access to bottled tap water. 
 
Physical Injury 
After anesthesia (sodium pentobarbital 2 mg/25 g), a laparotomy was perfomed to 
expose the colon. A colonic loop measuring approximately 3 cm was constructed by 
exteriorizing the colon.  Two polyethylene catheters (PE 60, 1 mm in outer diameter) 
one in the proximal end and the other through the anus approximately 1 cm above the 
anal verge at the end was introduced and secured in place.  The distal catheter served 
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as a port to introduce the quantum dots and the proximal catheter served as the port 
for collecting the exudates form the lumen of the colonic loop.  Once the colonic loop 
was constructed, a physical injury was made by applying a hemostat at low pressure 
without affecting the integrity of the colon.  After the injury, QDs conjugated with anti-
MPO antibody were introduced into the lumen of the colonic loop at a concentration of 
250nM in 0.5 ml of PBS.  The QD conjugates were allowed to be in contact with the 
injured mucosa for 15 minutes.  After 15 minutes, the colon was perfused with saline to 
remove non adhering QDs.  After an overdose of sodium pentobarbital, when the 
animal was dead, the distal part of the colon where physical injury was introduced was 
removed, washed again and snap frozen. The frozen section was embedded in tissue 
freezing medium/OCT and kept at -900C until sectioned. 
 
Induction of Colitis 
Colitis was induced by feeding mice with 4% DSS (30 – 40 kDA, ICN Biochemicals, 
Costa Mesa, California) for seven days.  Daily disease activity index (DAI) was 
measured according to our previously published methods.   On the  days of the 
experiment , mice were anesthetized with sodium pentobarbital and colonic loops were 
prepared as described above in the physical injury method.  After the preparation of 
the colonic loop, QDs conjugated with anti-MPO, anti-TNF-α, anti-IL-1α or anti-
testosterone were introduced either alone or simultaneously (anti-MPO, anti-TNF-α, 
anti-IL-1α together). MPO-antibody was conjugated to yellow and red QD’s with 
emission wavelength of 565nm and 655nm respectively, IL1α antibody was conjugated 
with 605nm emission Quantum Dots, and anti-TNF-α antibody was conjugated to near 
infrared QDs with an emission wavelength of 705nm. Anti-testosterone antibody 
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conjugate served as non-specific non-inflammatory biomarker control in the colon.  
These QD-antibody conjugates remained in contact with the mucosa for 15 minutes.  
After 15 minutes, the colon was perfused with saline to remove non adhering QDs.  
After an overdose of sodium pentobarbital, when the animal was dead the distal part of 
colon was removed, washed again and snap frozen. The frozen section was embedded 
in tissue freezing medium/OCT and kept at -900C until sectioned. The procedure 
described was repeated on various days of DSS feeding starting from Day 3 until the 
DAI reached 3. As described in our previous publications, DAI of 3 is indicative of 
severe disease. 
 
 
Histopathological study  and Confocal Microscopy 
The colonic tissue exposed to QDs and mounted in OCT was used to cut frozen 
sections. Thin sections of approximately 10 microns were cut with a cryostat machine 
and mounted on gelatin coated glass slides.  A total of 100 sections were obtained from 
each tissue. After every 4 sections 1 section was stained for H&E stain so as to have a 
good histological comparison to the QD stained tissue. H&E staining was performed 
according to established protocols. Sections were fixed by treating with Ethyl alcohol 
according to established protocols. Briefly, the frozen sections were kept at room 
temperature for 30 minutes. The sections were dipped in 100%, 90%, 70% and 50% 
Ethanol each for a period of 10 minutes. The sections were further washed in deionized 
water for a period of 15 minutes to remove the tissue freezing medium matrix.  The 
slides were dried, mounted with fluorescent medium with/ without DAPI (4',6-
diamidino-2-phenylindole,  a nucleus staining dye) and covered with a glass slip for 
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confocal microscopy. Adjacent sections were subsequently mounted on gelatin coated 
super frost slides (Fisher Scientific) using fluorescence mounting media (Vectashield). 
These sections were then imaged with a filter-free Spectral Confocal and Multiphoton 
Microscope (Leica TCS SP2 AOBS). Images were acquired with a 40X objective and a 
numerical aperture of 1.25. QDs were excited with a488nm Argon laser and the images 
were scanned with a wavelength range of 550nm to 580 nm for QDs emitting at 
565nm, 635nm to 670nm for QDs emitting at 655nm, and 685nm to 740nm for QDs 
emitting at 705nm. The Full Width at Half Maximum (FWHM) for the QD's used is 
about 30 nm. Thus a range of +/- 15nm around the emission maximum is sufficient to 
collect nearly all the QD fluorescence signal from a given emission line when working 
with a single wavelength. It avoids any optical crosstalk when working with multiple 
wavelength QDs as in the case of the co-localization study. A stack of images was 
collected every 0.7 µm along the Z-axis as well as with transmitted light for brightfield 
views. The gain and offset were adjusted for each channels to achieve an optimal 
dynamic range. A maximum projection images was obtained along the Z-axis, using the 
Leica Confocal Software. The Z stack accounts for all the QDs that might have diffused 
in the thick tissue at different level. All subsequent image processing steps were carried 
on these projection images using Image J (NIH, Bethesda, USA) [30, 31] and Adobe 
Photoshop (ADOBE), to filter the background noise and automate the image 
processing steps to achieve uniform analysis of the data. Background noise was 
calculated from the image by selecting an area outside the tissue and subtracting it 
from the total pixel value of the image. This is done automatically by the ROI plugin in 
ImageJ. Intensity values were then obtained based on an average image intensity using 
the multi measure mode of the Image J software. The plug-in calculates the total pixels 
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in the region selected which in this case was the whole image itself. The H&E sections 
were imaged with Leica Epifluorescence microscope with a 40X objective. 
Disease activity index 
Body weights, stool consistency, and occurrence of occult blood or gross rectal bleeding 
were determined daily, as previously described [21, 27]. An investigator blinded to the 
protocol (AK) measured the DAI.  The clinical parameters scored here in are 
comprehensive functional measures analogous to subjective clinical symptoms 
observed in human ulcerative colitis.  The precision of this scoring method has been 
validated by repeated studies. The DAI also correlates well with the degree of histologic 
damage measured as crypt score [21, 27, 28].   
The most severe clinical disease has a score of 3.0 and the value zero (0) represent the 
least severe clinical disease. DAI was measured starting from Day 3 daily, until the 
score reached 3 which generally occurred on Day 7 or 8 during DSS feeding. 
RESULTS 
Physical injury 
 
Figure 1.  Images from experiment 1, acute injury. Tissue section labeled with 565 nm QD / MPO antibody 
conjugate after acute injury inflicted to colon. Image is pseudocolored green (1A). Figure 1B shows the 
corresponding H& E staining of tissue section from the same colon showing transmural inflammation. Scale 
bar = 75μ  in confocal image and 48μ in H&E stained image. 
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To demonstrate the feasibility of using conjugated QDs to image MPO before 
implementing a disease model, a simple experiment was performed where colon was 
physically injured. The injured colon was exposed to QDs (emission wavelength 565 
nm) conjugated with anti-MPO antibody.  As illustrated in Figure 1A, there was 
transmural expression of MPO which corresponded with transmural inflammation as 
demonstrated in the H and E stained histological section (Figure 1B).   
Experimental colitis 
In the present study a 4% DSS feeding resulted in progressive non inflammatory crypt 
drop out, hyalination in the lamina propria and in the pericrypt region. With increasing 
days of DSS feeding and increasing DAI, there was corresponding increase in   
inflammation. On the 7th or 8th day when the disease was severe, there was significant 
weight loss of about 20%.  Histologically, on the 7th and 8th day, there was florid 
inflammation, loss of crypts and ulceration.  
 
Figure 2. Images from experiment 2, DSS model of colitis on Day 0 of DSS feed (control), with 565 QD-MPO 
antibody conjugates. Confocal maximum projection is shown as Figure 2A and H&E stained section as 
Figure 2B. Figure 2A shows absence of binding of QD-MPO antibody conjugate corresponding with lack of 
histologic inflammation (2B). Minimal inflammation is seen and QDs do not attach to colon due to absence 
of MPO expression. Scale bar = 75μ  in confocal image and 48μ in H&E stained image. 
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The study was done in three stages.  The first stage investigated the expression of MPO 
in relation to disease severity and tested the specificity of the QD construct to rule out 
non-specific binding.  Here, animals were fed DSS for eight days and a set of animals 
were sacrificed on day 0, day3, day 4, day6 and day 7 of DSS feeding.  On each of these 
days the colons were exposed to QDs with an excitation wavelength of 565 nm, which 
showed yellow fluorescence, when conjugated with anti-MPO.  The intent here was to 
image the expression of MPO in relation to progressing clinical disease activity.  
Figures 2A and 2B, 3A and 3B, 4A and 4B and 5A, 5B, 5c and 5D show the expression 
of MPO and corresponding histological pictures after H and E staining.    
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Figures 3A and 3B:  Images of colon taken on day three of DSS feeding.  There is minimal expression of 
MPO (3A). Histologically (3B), there was shortening of crypts with very minimal inflammation. 
 
Figures 4A and 4B: Images of colon taken on day four of DSS feeding. There is a slight increase in the 
expression of MPO (4A) as shown by increased fluorescence. Histologically (4B) there is further shortening 
of crypts with an increase in inflammatory infiltrates.  
Scale bar = 75μ  in confocal image and 48μ in H&E stained image. 
 
On day 0 (Figure 2A and 2B)  there was no disease activity. Histology revealed normal 
colon and confocal microscopy lack of expression of MPO.  On Day 3 (Figure 3A and 
3B) and on day 4 (Figure 4A and 4B), the DAI was 0.80 and 1.46 respectively.  
Histology on these days showed shortening of crypts with minimal inflammation. The 
confocal images of adjacent sections showed scattered expression of MPO in the lamina 
propria.   On day 6 the DAI was 2.46.   There was significant shortening of crypts with 
extensive inflammation evident from the H& E stained images (Figure 5B). 
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 Figure 5.  Figures represent images from experiment 2 from animals exposed to DSS for six and seven days. 
Figures 5A, 5C and 5D shows the binding of QD-MPO conjugate on days six and seven.  Figure 5B 
represents the corresponding histological picture on day six with shortening of crypts and increased 
infiltration of inflammatory cells. Scale bar = 75μ  in confocal image and 48μ in H&E stained image. 
 
 
From the confocal images it was evident that QDs  targeted MPO and entered the 
crypts as well (Figures 5A, 5C and 5D). On day 7 the DAI was 2.56.  Confocal 
microscopy showed increased expression of MPO in multiple areas in the lamina 
propria.  The images were quantified and the intensity values were plotted against time 
course of disease induction (Figure 6A and 6B).  This plot shows that the image 
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intensity correlates very well with progression and severity of disease, suggesting 
increased expression of MPO as disease progresses.   
 
Figure 6. A) Disease Activity Index (DAI) plot to monitor the progression of disease, B) Fluorescence 
intensity versus disease time period. Average intensity measurements are based on three different tissue 
sections for each day evaluated, and at every section 6-9 confocal maximum projection images were 
analyzed and averaged for their fluorescence intensity. Figure 6 shows mean intensity values and error bars 
indicate standard deviation. 
 
In the second stage, experiments were conducted to determine whether changing the 
QD size and emission wavelength would in any way affect the imaging of MPO.  In this 
part of the study, the QDs used were 6 nM in size, and showed fluorescence at 655 nm 
in the red region. Use of these QDs avoids overlap with the green tissue auto-
fluorescence. The experimental procedure was kept the same and animals were 
sacrificed on Day 3, Day 5 and Day 8 when the DAI was 0.11, 1.56 and 2.67 respectively.  
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 Figure 7: Images from day three of DSS feeding showing minimal inflammation (7B).  Figure 7B represents 
minimum binding of QD-MPO conjugate at 655 nn. Scale bar = 75μ  in confocal image and 48μ in H&E 
stained image. 
 
 
Figure 8:  Image 8A is the maximum projection fluorescent image for 655QD conjugates on day5 of DSS 
feed, showing widespread binding of the QD-MPO conjugate corresponding the severity of the disease as 
shown in Figure 8B. Scale bar = 75μ  in confocal image and 48μ in H&E stained image. 
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Figure 9: Confocal maximum projection image of 655 QDs from tissue sections on Day 8 of DSS feed 
(Figure 9A). H&E stain (9B) shows severe damage to tissue with total loss of crypts and halynation of the 
epithelial layer. In fluorescent images (Figure 9A) the QDS have labeled the whole tissue with increased 
intensity. S.L = smooth muscle layer. Scale bar = 75μ  in confocal image and 48μ in H&E stained image. 
 
On Day3, there was very little inflammation within the lamina propria.  Confocal 
microscopy showed localization of MPO-conjugated QDs right below the epithelium 
(Figure 7A), and H&E staining confirms the minimal inflammation (Figure 7B).  On 
Day 5, the H&E stained section showed increased inflammation and shortening of 
crypts (Figure 8B).  Confocal micrsopcopy (Figure 8A) showed increased expression of 
MPO very similar to that seen with QDs which fluoresced at 565 nm. On Day 8 when 
the DAI reached 2.67, the animals had lost significant weight with bloody diarrhea. The 
disease had progressed from the distal to the proximal colon with shortened colon.  
Histologically (Figure 9B) there was complete loss of crypts, appearance of mucosal 
erosions and frank ulceration.   
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 Figure 10. A) The Disease activity Index plot for experiment 3 (DSS colitis model labeling with QD655 
conjugates). The increase in DAI over the DSS feed time indicates progression of inflammation from mild to 
severe stage. B)  Fluorescence Intensity (A.U.) versus Disease Activity Index (DAI), C) The fluorescence 
intensity plot for MPO expression level at different days of DSS feed. The fluorescence intensity of multiple 
images of different sections from same animal were plotted against respective day of DSS feed.   
 
The confocal image (Figure 9A) showed higher concentration of MPO conjugated QDs 
as compared to Day 5 and Day 3 images. All images were processed with Image J 
software and intensity values in AU (arbitrary units) were averaged and plotted against 
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both time (day of DSS feeding) and Disease Activity Index (DAI). The plot (Figure 10) 
demonstrated consistent correlation of MPO expression as measured by QD intensity 
with the day of disease progression and the disease activity index (r = 0.96), similar to 
our earlier observations with 565 nm QDs.  
 
Figure 11: Tissue labeling with QD-testosterone antibody, during Day 8 of DSS feed. 
Figure 11A shows lack of QD-MPO conjugate in the lamina propria.  Figure 11B shows severely inflamed 
colon. Scale bar = 75μ  in confocal image and 48μ in H&E stained image. 
 
To demonstrate the specificity of the conjugate designed another experiment was 
performed where the QDs were conjugated to a non specific antibody. An anti 
testosterone antibody was selected due to the absence of testosterone in the colon. 
These QD-testosterone-antibody conjugates were tested in identical experiments as the 
MPO conjugates on day4 and day 6.  As shown in Figures 11A and 11B, the anti-
testosterone antibody bound to QDs had washed away and there was no binding of 
anti-testosterone antibody in the lamina propria despite severe colitis.  
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 Figure 12: Simultaneous targeting of three different markers on Day 3 of DSS feed.   Confocal 
maximum projection image Figure 12A shows IL1a targeting in green, Figure 12B MPO targeting 
in red, Figure 12C TNFa targeting in magenta and 12D is the H&E staining image. Only Figure 
12A shows minimal binding of QD-IL-1alpha conjugate.  There is minimal or lack of binding of QD-MPO 
(12B) and TNF alpha conjugage (12C).  Histology (12D) looks normal. 
 H&E stain image shows intact crypts with minimal inflammation. Image 12b shows very little 
presence of MPO and TNFα is absent (Image 12C). Scale bar = 75μ  in confocal image and 48μ in 
H&E stained image. 
 
In the last part of the study, three different QDs (5 nm, 6nm and 7nm original QD size) 
fluorescing at 605nm, 655nm and 705nm and conjugated with IL-1, MPO, and TNF-a 
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were used to detect the expression of these inflammation markers on day 3, day 6 and 
day 7 of the disease.  The DAI on these days was 0.80, 2.46 and 2.56 respectively. 
 
Figure 13: Simultaneous targeting of three different markers on Day 6 of DSS feed.   Confocal 
maximum projection image Figure 13A shows IL1a targeting in green, Figure 13B MPO targeting 
in red, Figure 13C TNFa targeting in magenta and 13D is the H&E staining image. Figures 13A, 
13B and 13C shows binding of QD-Il-1 alpha, MPO and TNF alpha conjugates in the crypts.  Arrows 
points toward the expression of markers. Scale bar = 75μ  in confocal image and 48μ in H&E stained 
image. 
On day 3, histology showed very mild disease (Figure 12D) with shortening of crypts 
and confocal microscopy showed weak expression of IL-1a and MPO and lack of 
expression of TNFa (Figures 12A, 12B and 12C). On day 6, as evidenced by histology, 
the inflammation had progressed gradually and in accordance to our previous 
observation, there was more shortening of crypts and the lamina propria was 
infiltrated with inflammatory cells  (Figure 13D). From the corresponding confocal 
images the QDs conjugates had bound all the three markers though the intensity of 
TNF-a was considerably less as compared to the other two markers (Figures 13A, 13B 
and 13C). However, on day 7, when the disease was severe (Figure 14E-H&E staining) 
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there was increased expression of IL-1a, MPO and TNF-a at the same location (Figures 
14A, 14B, 14C).  Figure 14D shows co0localization of all three markers simultaneously 
demonstrating that all three markers can be detected in a single setting. 
 
Figure 14: Colocalization of three inflammation markers targeted with QD conjugates. Confocal 
maximum projection images on Day 7 of DSS feed. Figure 14A shows IL1α marker targeted with 
605QDs, Figure 14B shows MPO marker targeted with 565QD, Figure 14C shows TNFα targeted 
with 705QDs. Figure 14E is the corresponding H&E stain. Image14 D shows colocalization of the 
three markers targeted with three different QDs. Scale bar = 75μ  in confocal image and 48μ in H&E 
stained image. 
 
 
Discussion: 
Inflammatory diseases comprise of a whole host of conditions such as rheumatoid 
arthritis, multiple sclerosis, asthma, inflammatory bowel diseases (IBD) and various 
other life-altering diseases including myocarditis.  In these diseases, inflammation 
begins as a defensive process to protect itself from harmful pathogens and chemicals. 
When this defense mechanism is uncontrolled, the integrity of tissue may be breached 
 22
resulting in damage to the vital organs, nervous, musculoskeletal systems and blood 
vessels. This breach permits soluble mediators of inflammation to be produced at the 
site, leukocytes, monocytes and lymphocytes to migrate towards the site and activate 
the immune system in a dysregulated manner effecting hyper-reactivity of lymphocytes 
eliciting Th1 and Th2 type immune responses [13, 32].  As a result of this abnormal 
immune activation, the surrounding tissue expresses a variety of enzymes, adhesion 
molecules, cytokines, proteins, lipid mediators, and growth factors that participate in 
tissue destruction and repair.  Sometimes this abnormal immune response attacks self, 
resulting in further tissue damage.  Though inflammatory reactions on the skin and 
other open areas on the body can be superficially visualized, in many cases when vital 
organs are affected, clinicians wait till overt signs and symptoms are presented, by that 
time destruction of the tissue in those vital organs has already progressed. Thus, in 
many cases it remains difficult to clearly diagnose these diseases.  There have been 
significant advances made by researchers in biochemistry, immunology and drug 
discovery fields in the identification of molecular signatures of inflammation and 
cancer, using complicated and cumbersome wet laboratory techniques.    A long 
standing goal in inflammation and inflammation-associated cancer research has been 
to develop imaging techniques that can detect inflammation and cancer at an early 
stage, to follow the progression of disease,  to predict how inflammation will behave 
after therapy and possibly facilitate appropriate therapy.  Recent technological 
advances in nanotechnology have simplified direct, quantitative identification of 
various biomarkers, in vitro, in situ and in vivo.  Thus the main objective of this study 
was to image the biomarkers of inflammation in situ utilizing the antibody-conjugated 
QDs in an established DSS model of experimental colitis in mice. The results of our 
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study showed that specific anti-MPO, anti-TNF-α and anti-Il-1α antibodies conjugated 
to QDs can detect those inflammation markers in linear relationship with the severity 
of the disease in this model.  Further, these QD conjugates can be simultaneously used 
to study the sequential expression of multiple markers in a single setting in this model. 
Finally, the results of our study showed that QDs, irrespective of their size and 
fluorescence emission wavelength, can be used alone or in combination to image the 
expression of these markers.  Thus this study demonstrated the application of QD 
imaging technology to detect the degree of inflammation in this model. We believe that 
this technology can also be used to monitor the progression of the disease and to aid in 
therapeutic decision making after treatment to facilitate the use of appropriate therapy.  
In this study, we elected to use MPO, TNF-a and IL-1a based upon the abundant 
information available on the role played by these markers in the development and 
progression of IBD and other inflammatory diseases. Myeloperoxidase is a stable and 
ubiquitous inflammatory biomarker for autoimmune, inflammatory diseases and 
cancer.   Thus we conducted our pilot studies after physical injury and follow up studies 
in the colitis model as a mean of standardizing our methods.  In the physical injury 
model, we used 2 nm size QDs conjugated with anti-MPO antibody (When the QD is 
conjugated to the anti-MPO antibody it is 30-50nm).  This study showed the 
expression of MPO in all layers of the colon 20 minutes after the induction of injury 
suggesting that the QDs can be used to detect the expression of MPO soon after injury 
reliably and reproducibly .  This observation provided us the impetus to follow the 
expression of MPO prior to and during the development of colitis in the DSS model of 
mouse colitis. The DSS model of colitis has been popularized by us to be one of the 
prominent models for understanding the pathogenesis of colitis as well as one of the 
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premier model of preclinical studies [21, 27].   In this model, when animals are fed 4% 
DSS, they develop colitis with an initial change of altered crypt architecture with 
shortening of crypts followed by the appearance of inflammation (around day 3), 
further shortening of crypts, crypt dropout, and finally loss of epithelium and 
ulceration.    All of these changes occur between the second and the eighth day of DSS 
feeding.   Thus, this model serves as a useful model to follow the expression of MPO 
during the development of the disease.  
In the past, investigators have attempted to measure the concentration of MPO during 
the course of the development of the disease in this model with limited success.  The 
methods and the amount of MPO produced in this model could be very low leading to 
inconsistent results. For instance, myeloperoxide measurements are generally carried 
out by measuring the oxidation activity of specific substrate in tissue homogenate or 
cell population either spectrophotometrically or by chemiluminescence methods [14, 
15, 33-36]. The spectrophotometric methods are based on either the oxidizing or 
chlorinating activity of MPO on O-dianisidine (O-DA), tetramethylbenzidine & 
measuring the absorbance at a specific wavelength [14, 15, 37].  Chemiluminescence 
(CL) methods are based on the measurement of intense light emitted by the oxidation 
of 5-amino-2,3-duhyrdo-1,4-phthalazinedione (luminol) by H2O2  in the isolated cell 
population [34, 35]. Though both assays are good at predicting MPO activity with 
chemiluminescence being more sensitive, these assays are conducted in vitro, are non- 
specific and semi-quantitative. A large background signal may be present due to 
presence of other tissue peroxidases, and hemeproteins may also mask true MPO 
recognition[33, 34]. In addition reduction of the dyes/substrate employed in these 
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assays may result in the formation of adducts with other radical products making the 
reproducibility an issue [38] 
Thus, new methods to measure MPO without altering the local environment are 
needed to image and quantify MPO at very low levels from the start of the 
inflammation process, during the progression of acute inflammation to chronicity, 
during the malignant transformation of the tissue and during treatment.  Thus we 
conducted our pilot studies after physical injury and follow up studies in the colitis 
model as a means of standardizing our methods.   
In the physical injury model, we used 2 nm  size QDs (emission wavelength 565 nm) 
conjugated with  anti-MPO antibody.  This study showed the expression of MPO in all 
layers of the colon 20 minutes after the induction of injury suggesting that the QDs can 
be used to detect the expression of MPO soon after injury to the animal as opposed to 
tedious extraction and immuno-histochemical techniques. This observation provided 
us the impetus to follow the expression of MPO temporally prior to and during the 
development of colitis in the DSS model of mouse colitis.    
The DSS model of colitis has been popularized by us to be one of the prominent models 
for understanding the pathogenesis of colitis as well as one of the premier model of 
preclinical studies. In this model, when animals are fed 4% DSS, they develop colitis 
with an initial change in the crypt architecture with shortening of crypts followed by 
the appearance of inflammation (around day 2 to 4).  After day 4, our previous study 
has shown, there will be further shortening of crypts, crypt dropout, loss of epithelium 
and ulceration (day 6 -8).   The DAI will increase from zero (day 0) to 4.0 on days 
seven or eight with animals gradually losing weight, change in the stool consistency 
from normal to diarrhea and occult to gross rectal bleeding [21, 27] .   All of these 
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changes occur between the second and the eighth day of DSS feeding. Thus, this model 
has served as a useful model to follow the development of the disease and for 
preclinical testing. 
In this study we evaluated the binding of anti-MPO bound QDs prior to and during the 
administration of DSS on days four and seven or eight when the disease was moderate 
and severe, respectively.  Our observations showed on day four the DAI was 1.67 
indicating mild colitis.  Histologcally, there was shortening of crypts and mild 
infiltration of neutrophils and other inflammatory cells in the lamina propria.  At this 
stage of the disease, there was scattered distribution of MPO as evidenced by QDs  in 
the lamina propria.   
The exact mechanism by which anti-MPO QDs entered the lamina propria is not clear.  
Previous studies have shown that QDs when administered in vivo have penetrated deep 
into the tissue including subcellular areas in the mouse brain [39].  Though the exact 
mechanism by which QDs penetrate tissue in our study remains to be elucidated, we 
suspect that in our study QDs may have penetrated passively into the lamina propria 
due to leakiness and ulcerations in the epithelium.  Studies done before [40, 41] have 
shown that exposure of the colon to DSS in rats results in decreased hydrophobicity 
and increased permeability, thus we believe that QDs may have entered the mucosa 
passively with DSS.   Furhermore, previous studies done by us have shown that the 
colonic epithelial barrier is disrupted as early as the third after feeding DSS [42]. In 
fact significant numbers of animals show occult bleeding at this stage thereby further 
substantiating that the colonic barrier was disrupted resulting in increased 
permeability thereby facilitating the passive entrance of QDs.    Questions remain 
whether QDs which enter the lamina propria also produce adverse effects of their own 
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on the existing inflammation.  There is a reasonable suspicion that QDs may be toxic; 
however, cellular studies have shown that QDs have not adversely affected the cellular 
function in terms of cellular growth, differentiation and expression of other subcellular 
markers [43-45].  Thus, we believe that the technique we have used to is capable of 
temporally imaging the expression MPO in this model.  Further studies are needed to 
determine whether we will able to detect changes in the MPO expression after 
treatment.   
The next step in our study was to rule out indigenous autofluorescence by using QDs 
with near infrared excitation.  Thus, we conjugated QDs of different size at 655 nm.  As 
shown in Figures 7, 8 and 9, our studies confirmed our initial finding that QDs of larger 
diameter at 655 nm showed similar results substantiating our observation as a 
reproducible method irrespective of the size and fluorescence of QDs. Another 
important observation here was that these anti-MPO QDs showed less indigenous 
autofluorescence, allowing us to exploit the use of more specific QDs with limited 
autofluorescence. 
 
We performed control studies to evaluate whether this observation was due to specific 
binding by using anti-testosterone antibody bound to QDs of the same size and 
fluorescence spectra and tested them in parallel on Day 6,  when the disease was most 
severe.  Anti-testosterone antibody may also have penetrated into the lamina propria; 
however, since testosterone is not expressed in the colon, these QDs would have been 
washed out during preparation of histological sections. Our studies showed that these 
QDs did not non-specifically bind to any of the cellular structures or the connective 
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tissue in the lamina propria. This suggested to us that the binding of anti-MPO QDs to 
the MPO expressed in the colon  was specific. 
In the next series of experiments our aim was to achieve simultaneous detection of 
multiple inflammatory markers. Experiments were repeated with the simultaneous use 
of anti-MPO (655nm), anti-IL-1a (605nm), and anti-TNFa  (705nm)  at various 
induction phases of colitis in this model and the expression of these markers was 
followed over a week. Our observations showed some interesting findings.  The 
expression of MPO was reproducible compared to our two previous experiments.   
Animals did not show the expression of TNFa until day 7 of the disease.  IL-1a 
appeared in correlation with MPO expression.  Simultaneous spectral analysis by 
confocal microscopy showed co-localization of these markers surrounding the areas of 
inflammation confirming previous observations from others that these markers 
together can cross into the lamina propria and specifically bind their respective 
markers in this model. The imaging windows were very specific for each QD and 
combining this to the narrow QD emission spectra, there is no cross talk between these 
three different QDs although their emission spectra may lie in proximity to each other. 
In our particular studies we have utilized confocal microscope, however, the image 
acquisition can be done using epilfluorescence microscope with appropriate filters for 
QDs (easily available) and employing similar image processing techniques to the ones 
demonstrated in this study. 
In summary, the results of our study demonstrate that the technique used by us is 
useful for tracking biomarkers of inflammation at various stages of disease.  
These observations open up the opportunities for using quantum dots in temporal 
imaging and the drug discovery process to monitor distribution of drugs in the tissue, 
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cellular and subcellular levels and at the same preclinical therapeutic monitoring.  The 
future objectives should include utilization of our methods described in this study for 
the in vivo detection of these markers longitudinally in the same animal.  The ultimate 
goal of course is to use these methods to replace biopsy and other invasive techniques 
which disturb the local environment and are unable to provide an accurate picture.  At 
present the use of QDs for direct imaging in humans may not be possible until all of the 
toxicitiy issues surrounding the use of QDs are resolved.   However, it will not preclude 
the use of bioconjugated QDs in vitro and in animals to understand the pathogenesis of 
disease and preclinical drug evaluations and other similar uses. 
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